IMPACT II


Also found in: Acronyms.

IMPACT II

Cardiology A clinical trial–Integrelin to Manage Platelet Aggregation to Combat Thrombosis–that evaluated the efficacy of integrilin as an adjunct to coronary intervention. See Acute myocardial infarction, Heparin, Hirulog, Unstable angina.
Mentioned in ?
References in periodicals archive ?
Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee decided that the IMPACT II trial of INTEGRILIN(TM) (antithrombotic injection) had shown positive results as an adjunct therapy in helping to prevent acute cardiac ischemic complications in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Integrelin was studied in the setting of coronary angioplasty in IMPACT II, a large, multi-center Phase III clinical trial.
Nasdaq: CORR) today announced preliminary results from IMPACT II, a 4,010 patient, 82 center trial of Integrelin(TM), a novel cardiovascular agent, in the setting of coronary angioplasty.